Clinical trials: Adalimumab
Ankylosing Spondylitis
Safety and Efficacy of Adalimumab in Patients With Active Ankylosing Spondylitis
The purpose of the study is to assess the safety and clinical efficacy of adalimumab in subjects with active ankylosing spondylitis
- Trial name
- NCT00195819
- Testing
- adalimumab (D2E7)
- Where
- 9 sites in Canada
- Volunteers
- 82 people
- Sponsor
- Abbott
Hidradenitis Suppurativa
Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa
This study investigates efficacy, safety and pharmacokinetics of adalimumab in Japanese subjects with moderate to severe hidradenitis suppurativa (HS).
- Trial name
- NCT02904902
- Testing
- adalimumab
- Where
- 8 sites in Japan
- Volunteers
- 15 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
Adalimumab in Combination With Methotrexate vs Methotrexate Alone in Early Rheumatoid Arthritis
The purpose of the study is to evaluate the effectiveness of adalimumab in combination with methotrexate compared to methotrexate alone on work disability in subjects with early rheumatoid arthritis
- Trial name
- NCT00234845
- Testing
- adalimumab, methotrexate
- Where
- United States
- Volunteers
- 148 people
- Sponsor
- Abbott
Psoriatic Arthritis
Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy
The primary objective of this study is to evaluate the effect of filgotinib compared to placebo as assessed by the American College of Rheumatology 20% improvement (ACR20) response in participants with active psoriatic arthritis…
- Trial name
- PENGUIN 1 (NCT04115748)
- Testing
- Filgotinib, Adalimumab
- Where
- 74 sites in United States, Australia and 11 more
- Volunteers
- 67 people
- Sponsor
- Gilead Sciences
Rheumatoid Arthritis
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will assess how safe and effective upadacitinib is in treating RA when compared to adalimumab in…
- Trial name
- SELECT- SWITCH (NCT05814627)
- Testing
- Upadacitinib, Adalimumab
- Where
- 218 sites in United States, Argentina and 23 more
- Volunteers
- 487 people
- Sponsor
- AbbVie
Psoriatic Arthritis
Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic Arthritis
The purpose of the study is to assess the long-term safety and clinical efficacy of adalimumab in treatment of moderate to severely active psoriatic arthritis
- Trial name
- NCT00195689
- Testing
- Human anti-TNF monoclonal antibody/adalimumab
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Abbott
Juvenile Idiopathic Arthritis
Active Juvenile Idiopathic Arthritis (JIA) Compassionate Use
The main objective of this study is to evaluate the safety of adalimumab in patients 2 to < 4 years of age or ≥ 4 years of age weighing < 15 kg, with moderately to severely active polyarticular juvenile idiopathic arthritis (JIA)…
- Trial name
- NCT00775437
- Testing
- Adalimumab
- Volunteers
- 32 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Healthy
Study Of PF-06410293 And Adalimumab In Healthy Subjects (REFLECTIONS B538-01)
This healthy volunteers study will evaluate 210 subjects who will receive a single sub-cutaneous dose of PF-06410293 or adalimumab (United States) or adalimumab (European Union).
- Trial name
- NCT01870986
- Testing
- PF-06410293, Humira (adalimumab-EU), Humira (adalimumab-US)
- Where
- 2 sites in United States, Belgium
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Pfizer
Arthritis, Juvenile Idiopathic
Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA)
This is a multicenter, Phase 3 randomized, placebo-controlled study designed to evaluate adalimumab in children 4 to 17 years old with polyarticular juvenile idiopathic arthritis (JIA) who are either methotrexate (MTX) treated or…
- Trial name
- NCT00048542
- Testing
- OLE BSA Adalimumab +/- MTX, OLE FD Adalimumab +/- MTX
- Where
- 31 sites in United States, Belgium and 6 more
- Volunteers
- 171 people
- Sponsor
- Abbott
Crohn's Disease
A Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease
Purpose of the study is to test whether adalimumab can induce clinical remission in subjects with active Crohn's disease when compared to placebo (an inactive substance)
- Trial name
- NCT00055523
- Testing
- Adalimumab (D2E7)
- Where
- 43 sites in United States
- Volunteers
- 300 people
- Sponsor
- Abbott
Rheumatoid Arthritis
Drug Use Investigation for Humira® - All Patient Investigation for Rheumatoid Arthritis
To clarify the following matters: Unknown adverse reactions (especially clinically significant adverse reactions) Incidence and conditions of occurrence of adverse reactions in the clinical setting Factors that may affect the…
- Trial name
- NCT01076959
- Where
- 1,723 sites in Japan
- Volunteers
- 7,972 people
- Sponsor
- Abbott
Psoriasis
Immediate Response With Adalimumab and Its Impact on Quality of Life and Other Comorbidity Factors in Patients With Moderate to Severe Plaque Psoriasis
W11-050 is a Mexican open label multicenter study that has been designed to further assess the safety and efficacy of adalimumab in the treatment of patients with active plaque psoriasis who have failed prior conventional…
- Trial name
- NCT01265823
- Testing
- Adalimumab
- Where
- 8 sites in Mexico
- Volunteers
- 150 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Psoriatic Arthritis
Efficacy and Safety of Humira® in Patients With Psoriatic Arthritis in Normal Medical Practice
This study is a documentation of effectiveness and safety of Humira in patients with psoriatic arthritis.
- Trial name
- NCT01111240
- Where
- 509 sites in Germany
- Volunteers
- 4,635 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Rheumatoid Arthritis
Efficacy of HUMIRA in Subjects With Active Rheumatoid Arthritis
The purpose of the study is to assess the efficacy of adalimumab in subjects with rheumatoid arthritis focusing on subject-reported outcomes and early response to treatment
- Trial name
- HERO (NCT00234897)
- Testing
- adalimumab
- Where
- United States
- Volunteers
- 1,938 people
- Sponsor
- Abbott
Rheumatoid Arthritis
A Study to Investigate the Safety and Efficacy of ABT-122 Given With Methotrexate in Subjects With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
This study is a Phase 2 randomized, double-blind, double-dummy, parallel-group study designed to assess the safety, tolerability, efficacy, pharmacokinetics and immunogenicity of multiple doses of ABT 122 in subjects with active…
- Trial name
- NCT02141997
- Testing
- adalimumab, ABT-122
- Volunteers
- 222 people
- Sponsor
- AbbVie
Arthritis, Rheumatoid
Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
The purpose of this study is to compare the effectiveness and safety of ABP 501 against adalimumab (HUMIRA®) in adults with moderate to severe rheumatoid arthritis (RA) who have an inadequate response to methotrexate (MTX).
- Trial name
- NCT01970475
- Testing
- ABP 501, Adalimumab
- Where
- 11 sites in United States, Canada and 2 more
- Volunteers
- 526 people
- Sponsor
- Amgen
Rheumatoid Arthritis
A Study Comparing SB5 to Humira® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
This is a randomised, double-blind, parallel group, multicentre clinical study to evaluate the efficacy, safety, tolerability, pharmacokinetics and immunogenicity of SB5 compared to Humira® in subjects with moderate to severe RA…
- Trial name
- NCT02167139
- Testing
- Humira (adalimumab), SB5 (proposed biosimilar to adalimumab)
- Where
- 2 sites in Lithuania, Poland
- Volunteers
- 544 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Healthy
To Compare the Pharmacokinetics and Safety of CT-P17 and Humira in Healthy Subjects
This is a Phase 1, Randomized, Double-blind, Three-arm, Parallel group, Single-dose Study to Compare the Pharmacokinetics and Safety of CT-P17 and Humira (US licensed Humira and EU-approved Humira) in Healthy Subjects
- Trial name
- NCT03970824
- Testing
- CT-P17, US-licensed Humira, EU-approved Humira
- Where
- 9 sites in South Korea
- Volunteers
- 312 people, healthy volunteers welcome
- Sponsor
- Celltrion
Crohn's Disease
Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects With Crohn's Disease and Who Participated and Successfully Completed M14-115
The purpose of this study is to evaluate the long term efficacy, safety, and tolerability of repeated administration of adalimumab in participants with Crohn's disease.
- Trial name
- NCT02185014
- Testing
- Adalimumab
- Volunteers
- 252 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate
This study is conducted to evaluate the short (12 Weeks) and long term (104 Weeks) efficacy of Certolizumab Pegol compared with Adalimumab both in combination with Methotrexate (MTX) in the treatment of moderate to severe…
- Trial name
- NCT01500278
- Testing
- Certolizumab Pegol (CZP), Adalimumab (ADA), Methotrexate (MTX)
- Where
- 175 sites in United States, Australia and 18 more
- Volunteers
- 915 people
- Sponsor
- UCB Pharma SA